DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 1357--------------------------------------------------
       (Abst.) Predictors of severity and functional outcome in Tysabri
       -associated PML
       By: agate Date: September 12, 2016, 10:46 pm
       ---------------------------------------------------------
       From PubMed, September 8, 2016:
       [quote]Mult Scler. 2016 Sep 6.
       Predictors of severity and functional outcome in
       natalizumab-associated progressive multifocal
       leukoencephalopathy
       Hoepner R1, Kolb EM2, Dahlhaus S3, Hellwig K2, Adams O4, Kleiter
       I2, Salmen A5, Schneider R2, Lukas C6, Chan A5, Berger JR7, Gold
       R2.
       Author information
       1Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany roberthoepner@gmx.de.
       2Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany.
       3Department of Neurology, Alfried Krupp Hospital, Essen,
       Germany.
       4Department of Virology, Heinrich Heine University, Düsseldorf,
       Germany.
       5Department of Neurology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany/Department of Neurology, University
       Hospital Bern and University of Bern, Bern, Switzerland.
       6Department of Radiology, St. Josef Hospital, Ruhr University
       Bochum, Bochum, Germany.
       7Department of Neurology, University of Pennsylvania,
       Philadelphia, PA, USA.
       OBJECTIVE:
       Progressive multifocal leukoencephalopathy (PML) is an emerging
       complication of immunosuppressive therapies, especially
       natalizumab in multiple sclerosis (MS). Factors associated with
       functional outcome of natalizumab-associated PML
       (natalizumab-PML) have not been sufficiently described.
       METHODS:
       We retrospectively analyzed medical records of all patients with
       natalizumab-PML (n = 32) treated in our hospital
       since 2009. Disability measured by Expanded Disability Status
       Scale (EDSS) at two different time points (highest available
       EDSS during PML and last available EDSS after PML diagnosis)
       served as functional outcome parameters. Clinical, laboratory,
       and imaging data were analyzed for association with functional
       outcome by applying Spearman's rho and multivariate regression
       analysis.
       RESULTS:
       In all, 31/32 patients survived PML. A poor functional outcome
       was associated with higher age, higher initial John Cunningham
       virus (JCV) copy number in cerebrospinal fluid (CSF), and more
       extensive PML lesions on initial magnetic resonance imaging
       (MRI). No association between functional outcome and the
       duration of natalizumab therapy or a delayed PML diagnosis was
       observed.
       CONCLUSION:
       This study will be useful for neurological practice to estimate
       functional outcome or disease severity of natalizumab-PML in
       primary care settings.[/quote]
  HTML http://www.ncbi.nlm.nih.gov/pubmed/27600113
  HTML http://www.ncbi.nlm.nih.gov/pubmed/27600113
       *****************************************************